Corporate News

Niagen Bioscience (NAGE) closed the trading session on Friday, 23 April 2026, down 1.59 % at 04:29 AM Central Europe time. The share price stood at USD 2.52, a decline from the previous close. The company’s total outstanding shares amount to 79.3 million. Market capitalization is currently USD 199 million. In the last 24 hours, approximately USD 1.6 million worth of shares were exchanged.

Since the end of the previous month, NAGE shares have fallen 20.06 %. The 200‑day simple moving average is USD 4.06. The highest price recorded over the past 52 weeks was USD 7.95 on 11 May 2025; the 52‑week low was USD 2.43 on 21 October 2026.

  • Rgc (RGCO) – down 2.51 %, current price USD 23.05, market capitalization USD 236.2 million, P/E ratio 16.86.
  • Greenwich Lifesciences (GLSI) – up 2.03 %, current price USD 15.48, market capitalization USD 238.4 million.
  • Hirequest (HQI) – down 4.62 %, current price USD 16.51, market capitalization USD 237.7 million, P/E ratio 29.92.
  • Immersion (IMMR) – up 0.56 %, current price USD 7.18, market capitalization USD 237.8 million, P/E ratio 21.3.
  • Tailwind 20 Acquisitio (TDWD) – down 0.10 %, current price USD 10.12, market capitalization USD 238.5 million.

About Niagen Bioscience

Niagen Bioscience is a subsidiary of ChromaDex Corporation, a company headquartered in Los Angeles, United States, that operates in the life‑sciences tools and services sector. ChromaDex focuses on research related to nicotinamide adenine dinucleotide (NAD⁺), a molecule significant in healthy‑aging studies. The company provides services and resources to U.S. customers and is listed on the Nasdaq stock exchange. Further information is available on the company’s website at www.chromadex.com .